Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

• Status: Enrolling by invitation
• Trial end date: 2025-06-13
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the long-term safety and efficacy of Bimatoprost SR in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Patients who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR

Exclusion Criteria:

• Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception during the study

• Concurrent or anticipated enrollment in another investigational drug or device study during the present study

• Any condition which would preclude the patient's ability to comply with study requirements, including completion of the study

• Patients who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092